今年透過SPARK Global我們請到多位致力於疫苗及藥品開發領域的業界專家，與會者可以了解SPARK Global及其對於COVID-19所做的努力，並一窺市面上唯一鼻噴劑型流感四價疫苗FluMist的研發過程，另外本次也會有SPARK Stanford團隊一路成為上市公司Eidos Therapeutics的成長故事，外加曾帶領全球臨床試驗的業師剖析licensing out的挑戰與技巧。期待國內各方產學研界夥伴們一同參與此盛會!

In the 2021 SPARK Translational Symposium, SPARK Taiwan invites leading industry experts through SPARK Global on vaccines and drugs developments. The contents include SPARK Global and its effort to COVID-19 from Dr. Daria Mochly-Rosen, the development process of FluMist which is the only nasal spray influenza quadrivalent vaccine on the market by Dr. Mark Backer.

In the second half, there will be the success story of Dr. Isabella Graef of Eidos Therapeutics leading her SPARK Stanford team from the academic to have a major product, and also licensing out strategy by Dr. Lyn Frumkin, who has led global clinical trials. We look forward to all partners in the industry, academia, and research circles participating in this grand event !

Topics & Speakers

SPARK Global & COVID-19 effort      

Prof. Daria Mochly-Rosen
Founder and co-Director of SPARK At Stanford,
Professor of Chemical and Systems Biology, Stanford University
School of Medicine, California, USA

The development of flu vaccines and FluMist

Dr. Mark Backer
General Manager, Alava Biopharm Partners
Advisor, Stanford SPARK Program in Translational Research

Development of Small Molecule to Treat Amyloidosis (TBD)

Isabella Graef, MD, PhD
Assistant Professor of Stanford University
Scientific Co-Founder, Eidos Therapeutics

Biotechnology Opportunities- Assessing Their Attractiveness

Lyn Frumkin, MD, PhD
Advisor, Stanford SPARK Program in Translational Research